MX2018001994A - Proceso de replegamiento mejorado para los fragmentos de anticuerpo. - Google Patents

Proceso de replegamiento mejorado para los fragmentos de anticuerpo.

Info

Publication number
MX2018001994A
MX2018001994A MX2018001994A MX2018001994A MX2018001994A MX 2018001994 A MX2018001994 A MX 2018001994A MX 2018001994 A MX2018001994 A MX 2018001994A MX 2018001994 A MX2018001994 A MX 2018001994A MX 2018001994 A MX2018001994 A MX 2018001994A
Authority
MX
Mexico
Prior art keywords
fragments
antibody
refolding process
ranibizumab
improved refolding
Prior art date
Application number
MX2018001994A
Other languages
English (en)
Inventor
Mishra Ashok
Sorab Mody Rustom
Pandey Ashish
Somani Sandeep
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MX2018001994A publication Critical patent/MX2018001994A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención proporciona un proceso de replegamiento de Ranibizumab, en donde la disolución solubilizada de cadena pesada y/o cadena ligera de Ranibizumab tratada con un búfer de replegamiento en condiciones adecuadas que incluyen pH, temperatura y periodo de incubación y el cambio de pH y temperatura se realiza a intervalos adecuados para obtener alta calidad y cantidad de la proteína replegada.
MX2018001994A 2015-08-17 2016-08-17 Proceso de replegamiento mejorado para los fragmentos de anticuerpo. MX2018001994A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3118MU2015 2015-08-17
PCT/IB2016/054926 WO2017029620A1 (en) 2015-08-17 2016-08-17 An improved refolding process for antibody's fragments

Publications (1)

Publication Number Publication Date
MX2018001994A true MX2018001994A (es) 2018-11-09

Family

ID=56936450

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001994A MX2018001994A (es) 2015-08-17 2016-08-17 Proceso de replegamiento mejorado para los fragmentos de anticuerpo.

Country Status (19)

Country Link
US (1) US10781250B2 (es)
EP (1) EP3337820B1 (es)
JP (1) JP6755939B2 (es)
CN (1) CN108026165A (es)
AU (1) AU2016307976A1 (es)
CA (1) CA2993907A1 (es)
DK (1) DK3337820T3 (es)
ES (1) ES2843558T3 (es)
HK (1) HK1254752A1 (es)
HR (1) HRP20210067T1 (es)
HU (1) HUE052993T2 (es)
LT (1) LT3337820T (es)
MX (1) MX2018001994A (es)
PH (1) PH12018500362A1 (es)
PL (1) PL3337820T3 (es)
PT (1) PT3337820T (es)
RU (1) RU2018109102A (es)
WO (1) WO2017029620A1 (es)
ZA (1) ZA201801498B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
KR20240049657A (ko) * 2017-03-24 2024-04-16 카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 재조합 항체 단편을 정제하는 방법
JP7282689B2 (ja) * 2017-05-19 2023-05-29 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ リフォールディングした組み換えヒト化ラニビズマブの製造方法
CN111128293B (zh) * 2019-11-25 2020-11-10 苏州纽博立科技有限公司 一种抗体药物生产工艺中碎片的修复方法
CN113073092A (zh) * 2021-04-15 2021-07-06 宁波瑞林生物科技有限公司 重组人组织型激肽释放酶及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US20080305516A1 (en) * 2004-11-30 2008-12-11 Kristian Kjaergaard Method of Producing Antibodies
CN100336824C (zh) * 2005-12-19 2007-09-12 百奥泰生物科技(广州)有限公司 一种重组蛋白的高效变复性的方法
CN101505794B (zh) * 2006-07-10 2013-09-04 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 穿过上皮和/或内皮层的scFV抗体
US20080125580A1 (en) * 2006-07-14 2008-05-29 Genentech, Inc. Refolding of Recombinant Proteins
JP5168604B2 (ja) * 2008-05-08 2013-03-21 味の素株式会社 タンパク質のリフォールディング方法
CN102206272B (zh) * 2009-12-11 2014-10-01 普罗特奥姆技术公司 生产重组α1-抗胰蛋白酶的方法
AU2011317021B2 (en) * 2010-10-20 2015-07-09 Medimmune, Llc Methods for processing inclusion bodies
US10065987B2 (en) * 2013-02-12 2018-09-04 Bristol-Myers Squibb Company High pH protein refolding methods
US9914770B2 (en) * 2013-04-30 2018-03-13 Intas Pharmaceuticals Ltd Cloning, expression and purification method for the preparation of ranibizumab
CN103804486B (zh) * 2014-01-20 2017-05-17 安徽安科生物工程（集团）股份有限公司 一种提高重组人干扰素α2b天然构象含率的制备工艺

Also Published As

Publication number Publication date
US20180230206A1 (en) 2018-08-16
CN108026165A (zh) 2018-05-11
HUE052993T2 (hu) 2021-06-28
AU2016307976A1 (en) 2018-03-08
ES2843558T3 (es) 2021-07-19
HRP20210067T1 (hr) 2021-03-05
US10781250B2 (en) 2020-09-22
JP2018529654A (ja) 2018-10-11
DK3337820T3 (da) 2021-01-18
LT3337820T (lt) 2021-02-10
ZA201801498B (en) 2018-12-19
PT3337820T (pt) 2021-01-19
JP6755939B2 (ja) 2020-09-16
CA2993907A1 (en) 2017-02-23
RU2018109102A3 (es) 2020-01-30
PH12018500362A1 (en) 2018-08-29
HK1254752A1 (zh) 2019-07-26
WO2017029620A1 (en) 2017-02-23
PL3337820T3 (pl) 2021-11-22
EP3337820A1 (en) 2018-06-27
RU2018109102A (ru) 2019-09-19
EP3337820B1 (en) 2020-10-14

Similar Documents

Publication Publication Date Title
PH12018500362A1 (en) An improved refolding process for antibodys fragments
ZA202211057B (en) Anti-trem2 antibodies and methods of use thereof
MY194764A (en) Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
GEP20207162B (en) Lag-3-binding molecules and methods of use thereof
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
MD3303379T2 (ro) Agenți de legare TIGIT și utilizări ale acestora
MX2019010922A (es) Anticuerpos anti-phf-tau y usos de estos.
EA201790342A1 (ru) Антитела к trem2 и способы их применения
EA201792221A1 (ru) Антитела против сортилина и способы их применения
PE20170665A1 (es) Anticuerpos anti-tau humanizados
TN2012000040A1 (en) High affinity human antibodies to human angiopoietin -2
EA201990778A1 (ru) Анти-il-33 антитела и их применение
PH12017500094A1 (en) Novel anti-human tie-2 antibody
EA201992206A1 (ru) Моноклональное антитело к pd-l1
MD3355919T2 (ro) Terapie combinată cu utilizarea inhibitorilor factorului de creștere și diferențiere uman 15 (GDF-15) și a blocanților punctelor de control imunitar
MX2023010076A (es) Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas.
EA202190807A1 (ru) Антитела к синуклеину
EA201792325A1 (ru) Способ увеличения процентного содержания мономерного антитела в fab-dsfv мультимерных частицах
PE20220004A1 (es) Anticuerpos monoclonales especificos para el antigeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, utiles para la deteccion y el diagnostico de la infeccion causada por vrsh
EA202092088A1 (ru) Антитела анти-phf-тау и их применение
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
EA201891594A1 (ru) Антитела к il-17c
EA201890005A1 (ru) АКТИВАТОР С НИЗКИМ ЗНАЧЕНИЕМ pH ДЛЯ ВЕЩЕСТВ-ЗАМЕНИТЕЛЕЙ КЛИНКЕРА
EA201892231A1 (ru) Способ очистки белка
EA202090864A1 (ru) Моноклональное антитело к il-5r